Lexicon Pharmaceuticals Completes Enrollment Of Pivotal Phase 3 Sonata-Hcm Study Of Sotagliflozin In Symptomatic Non-Obstructive And Obstructive Hypertrophic Cardiomyopathy (Hcm)
LXRX•Phase 3 Sonata-HCM study enrollment completed
Lexicon Pharmaceuticals Inc LXRX.O:
- Lexicon Pharmaceuticals completes enrollment of pivotal Phase 3 Sonata-HCM study of sotagliflozin in symptomatic non-obstructive and obstructive hypertrophic cardiomyopathy (HCM)
- Lexicon Pharmaceuticals said topline results for the Sonata-HCM trial are anticipated in Q1 2027
